vs

Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and NexPoint Real Estate Finance, Inc. (NREF). Click either name above to swap in a different company.

NexPoint Real Estate Finance, Inc. is the larger business by last-quarter revenue ($11.1M vs $9.2M, roughly 1.2× Foghorn Therapeutics Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -234.3%, a 450.9% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs -48.8%).

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.

NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.

FHTX vs NREF — Head-to-Head

Bigger by revenue
NREF
NREF
1.2× larger
NREF
$11.1M
$9.2M
FHTX
Growing faster (revenue YoY)
FHTX
FHTX
+272.6% gap
FHTX
223.8%
-48.8%
NREF
Higher net margin
NREF
NREF
450.9% more per $
NREF
216.6%
-234.3%
FHTX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FHTX
FHTX
NREF
NREF
Revenue
$9.2M
$11.1M
Net Profit
$-21.7M
$24.0M
Gross Margin
Operating Margin
-258.2%
Net Margin
-234.3%
216.6%
Revenue YoY
223.8%
-48.8%
Net Profit YoY
-11.1%
58.7%
EPS (diluted)
$-0.35
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FHTX
FHTX
NREF
NREF
Q4 25
$9.2M
$11.1M
Q3 25
$8.2M
$12.5M
Q2 25
$7.6M
$12.1M
Q1 25
$6.0M
$11.5M
Q4 24
$2.9M
$21.7M
Q3 24
$7.8M
$12.5M
Q2 24
$6.9M
$6.7M
Q1 24
$5.0M
$-12.8M
Net Profit
FHTX
FHTX
NREF
NREF
Q4 25
$-21.7M
$24.0M
Q3 25
$-15.8M
$50.9M
Q2 25
$-17.9M
$22.3M
Q1 25
$-18.8M
$26.0M
Q4 24
$-19.5M
$15.2M
Q3 24
$-19.1M
$23.3M
Q2 24
$-23.0M
$12.1M
Q1 24
$-25.0M
$-14.6M
Operating Margin
FHTX
FHTX
NREF
NREF
Q4 25
-258.2%
Q3 25
-226.9%
Q2 25
-279.2%
Q1 25
-385.0%
Q4 24
-840.5%
Q3 24
-305.5%
Q2 24
-386.6%
Q1 24
-558.3%
Net Margin
FHTX
FHTX
NREF
NREF
Q4 25
-234.3%
216.6%
Q3 25
-194.4%
407.0%
Q2 25
-237.3%
184.5%
Q1 25
-316.4%
225.6%
Q4 24
-682.9%
69.9%
Q3 24
-244.9%
186.4%
Q2 24
-333.6%
179.7%
Q1 24
-495.4%
114.3%
EPS (diluted)
FHTX
FHTX
NREF
NREF
Q4 25
$-0.35
$0.47
Q3 25
$-0.25
$1.14
Q2 25
$-0.28
$0.54
Q1 25
$-0.30
$0.70
Q4 24
$-0.23
$0.71
Q3 24
$-0.31
$0.74
Q2 24
$-0.45
$0.40
Q1 24
$-0.59
$-0.83

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FHTX
FHTX
NREF
NREF
Cash + ST InvestmentsLiquidity on hand
$80.9M
$31.1M
Total DebtLower is stronger
$771.2M
Stockholders' EquityBook value
$-108.5M
$388.0M
Total Assets
$198.1M
$5.3B
Debt / EquityLower = less leverage
1.99×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FHTX
FHTX
NREF
NREF
Q4 25
$80.9M
$31.1M
Q3 25
$89.3M
$17.9M
Q2 25
$72.6M
$9.1M
Q1 25
$61.0M
$19.2M
Q4 24
$55.5M
$3.9M
Q3 24
$57.7M
$34.7M
Q2 24
$138.9M
$4.3M
Q1 24
$79.3M
$13.5M
Total Debt
FHTX
FHTX
NREF
NREF
Q4 25
$771.2M
Q3 25
$720.9M
Q2 25
$815.6M
Q1 25
$831.5M
Q4 24
$799.3M
Q3 24
$815.5M
Q2 24
$861.0M
Q1 24
$843.3M
Stockholders' Equity
FHTX
FHTX
NREF
NREF
Q4 25
$-108.5M
$388.0M
Q3 25
$-89.7M
$375.4M
Q2 25
$-76.7M
$348.2M
Q1 25
$-61.7M
$343.7M
Q4 24
$-45.5M
$336.5M
Q3 24
$-28.3M
$335.8M
Q2 24
$-14.3M
$327.5M
Q1 24
$-97.5M
$327.1M
Total Assets
FHTX
FHTX
NREF
NREF
Q4 25
$198.1M
$5.3B
Q3 25
$205.0M
$5.3B
Q2 25
$226.2M
$5.4B
Q1 25
$258.7M
$5.4B
Q4 24
$284.0M
$5.4B
Q3 24
$308.4M
$5.7B
Q2 24
$328.6M
$6.6B
Q1 24
$255.0M
$7.1B
Debt / Equity
FHTX
FHTX
NREF
NREF
Q4 25
1.99×
Q3 25
1.92×
Q2 25
2.34×
Q1 25
2.42×
Q4 24
2.38×
Q3 24
2.43×
Q2 24
2.63×
Q1 24
2.58×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FHTX
FHTX
NREF
NREF
Operating Cash FlowLast quarter
$-22.3M
$-4.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FHTX
FHTX
NREF
NREF
Q4 25
$-22.3M
$-4.5M
Q3 25
$-18.9M
$8.1M
Q2 25
$-21.0M
$3.3M
Q1 25
$-24.0M
$16.0M
Q4 24
$-24.5M
$4.4M
Q3 24
$-21.0M
$14.7M
Q2 24
$-25.5M
$-7.5M
Q1 24
$-29.3M
$17.7M
Free Cash Flow
FHTX
FHTX
NREF
NREF
Q4 25
Q3 25
Q2 25
$-21.0M
Q1 25
$-24.0M
Q4 24
$-25.0M
Q3 24
$-21.3M
Q2 24
$-25.6M
Q1 24
$-29.4M
FCF Margin
FHTX
FHTX
NREF
NREF
Q4 25
Q3 25
Q2 25
-278.2%
Q1 25
-403.2%
Q4 24
-875.3%
Q3 24
-273.0%
Q2 24
-371.0%
Q1 24
-583.1%
Capex Intensity
FHTX
FHTX
NREF
NREF
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.3%
Q1 25
0.5%
Q4 24
16.8%
Q3 24
4.0%
Q2 24
0.2%
Q1 24
2.0%
Cash Conversion
FHTX
FHTX
NREF
NREF
Q4 25
-0.19×
Q3 25
0.16×
Q2 25
0.15×
Q1 25
0.62×
Q4 24
0.29×
Q3 24
0.63×
Q2 24
-0.62×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons